[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO991048L - Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) - Google Patents

Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)

Info

Publication number
NO991048L
NO991048L NO991048A NO991048A NO991048L NO 991048 L NO991048 L NO 991048L NO 991048 A NO991048 A NO 991048A NO 991048 A NO991048 A NO 991048A NO 991048 L NO991048 L NO 991048L
Authority
NO
Norway
Prior art keywords
pde
tnf
preparation
type
necrosis factor
Prior art date
Application number
NO991048A
Other languages
English (en)
Other versions
NO991048D0 (no
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO991048D0 publication Critical patent/NO991048D0/no
Publication of NO991048L publication Critical patent/NO991048L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) og deres farmasøytisk akseptable salter, hvor R, Rt og R2 er som definert her. Oppfinnelsen angår videre farmasøytiske blandinger som inneholder og fremgangsmåter for å anvende forbindelsene med formel (I) eller deres akseptable salter, for inhibering av fosfodiesterase (PDE) type IV eller produksjonen av tumornekrosefaktdf (TNF) i et pattedyr. Oppfinnelsen angår også mellomprodukter som kan brukes ved fremstillingen av forbindelsene med formel (I).
NO991048A 1996-09-04 1999-03-03 Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF) NO991048L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2544696P 1996-09-04 1996-09-04
PCT/IB1997/001023 WO1998009961A1 (en) 1996-09-04 1997-08-25 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (2)

Publication Number Publication Date
NO991048D0 NO991048D0 (no) 1999-03-03
NO991048L true NO991048L (no) 1999-05-03

Family

ID=21826124

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991048A NO991048L (no) 1996-09-04 1999-03-03 Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)

Country Status (35)

Country Link
US (1) US6262040B1 (no)
EP (1) EP0931075A1 (no)
JP (2) JP3554337B2 (no)
KR (1) KR100338610B1 (no)
CN (1) CN1234031A (no)
AP (1) AP795A (no)
AR (1) AR008162A1 (no)
AU (1) AU724549B2 (no)
BG (1) BG64447B1 (no)
BR (1) BR9712005A (no)
CA (1) CA2264798A1 (no)
CO (1) CO4600636A1 (no)
DZ (1) DZ2303A1 (no)
EA (1) EA002113B1 (no)
GT (1) GT199700102A (no)
HN (1) HN1997000126A (no)
HR (1) HRP970478B1 (no)
HU (1) HUP9903248A3 (no)
ID (1) ID18157A (no)
IL (1) IL128642A0 (no)
IS (1) IS4979A (no)
MA (1) MA26439A1 (no)
NO (1) NO991048L (no)
NZ (1) NZ334213A (no)
OA (1) OA10985A (no)
PA (1) PA8437301A1 (no)
PE (1) PE107998A1 (no)
PL (1) PL332187A1 (no)
SK (1) SK27299A3 (no)
TN (1) TNSN97148A1 (no)
TR (1) TR199900481T2 (no)
TW (1) TW402595B (no)
WO (1) WO1998009961A1 (no)
YU (1) YU11299A (no)
ZA (1) ZA977903B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
SK6262000A3 (en) * 1997-11-04 2002-03-05 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
SI1212089T1 (sl) 1999-08-21 2006-08-31 Altana Pharma Ag Sinergisticna kombinacija roflumilasta in salmeterola
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
EP1389467B1 (en) 2001-05-23 2013-07-03 Mitsubishi Tanabe Pharma Corporation Therapeutic composition for the regenerative treatment of cartilage diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CA2481385A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003231950A1 (en) * 2002-05-30 2003-12-19 Celgene Corporation Modulating cell differentiation and treating myeloproliferative disorders with JNK/MKK inhibitors
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
DE60334243D1 (de) * 2002-11-19 2010-10-28 Memory Pharmaceutical Corp Pyridin-n-oxidverbindungen alsphosphodiesterase-4-inhibitoren
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06002608A (es) 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MXPA06009462A (es) 2004-02-27 2007-03-15 Hoffmann La Roche Derivados pirazolo heteroaril fusionados.
EP1737865A1 (en) 2004-02-27 2007-01-03 F.Hoffmann-La Roche Ag Fused derivatives of pyrazole
BRPI0508107A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados de indazol e composições farmacêuticas contendo os mesmos
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0510980A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina para o tratamento do crescimento anormal de células
US20080015190A1 (en) * 2004-07-12 2008-01-17 Chakravarty Prasun K Inhibitors of Histone Deacetylase
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
EP1891060A2 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv
WO2007023111A2 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
ATE542800T1 (de) 2006-01-31 2012-02-15 Array Biopharma Inc Kinasehemmer und ihre anwendungsverfahren
CA2661850A1 (en) 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
CA2671543A1 (en) * 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US8569512B2 (en) * 2009-03-23 2013-10-29 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
WO2011133750A1 (en) * 2010-04-22 2011-10-27 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
MX2019005786A (es) * 2016-11-18 2019-08-26 Merck Sharp & Dohme Derivados de indazol utiles como inhibidores de diacilglicerido o-aciltransferasa 2.
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
WO2022256303A1 (en) * 2021-05-31 2022-12-08 Genscript Usa Inc. Electrografted films for dna synthesis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531433A (no) 1953-06-17
US4665397A (en) 1983-11-01 1987-05-12 Universal Photonics, Inc. Apparatus and method for a universal electronic locking system
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
JPS6250751A (ja) * 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
AU626980B2 (en) 1989-02-02 1992-08-13 Astellas Pharma Inc. Tetrahydrobenzimidazole derivatives
KR100188801B1 (ko) * 1990-05-18 1999-06-01 엥겔하르트 라피체 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
CZ3696A3 (en) * 1993-07-06 1997-06-11 Pfizer Bicyclic tetrahydropyrazolepyridines per se and for treating diseases, and pharmaceutical compositions based thereon
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE69508568T2 (de) * 1994-02-17 1999-10-21 American Home Products Corp., Madison Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung
WO1995027692A1 (en) * 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
JPH08143525A (ja) * 1994-11-21 1996-06-04 Banyu Pharmaceut Co Ltd ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
ES2201299T3 (es) * 1996-06-25 2004-03-16 Pfizer Inc. Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`.
ATE211740T1 (de) * 1996-06-27 2002-01-15 Pfizer Substituierte indazolderivate

Also Published As

Publication number Publication date
AU724549B2 (en) 2000-09-28
CA2264798A1 (en) 1998-03-12
PA8437301A1 (es) 1999-12-27
TW402595B (en) 2000-08-21
PL332187A1 (en) 1999-08-30
KR20000068421A (ko) 2000-11-25
IL128642A0 (en) 2000-01-31
YU11299A (sh) 2001-07-10
IS4979A (is) 1999-02-16
OA10985A (en) 2001-11-01
EA199900183A1 (ru) 1999-08-26
JP2004217668A (ja) 2004-08-05
US6262040B1 (en) 2001-07-17
AU3781397A (en) 1998-03-26
AR008162A1 (es) 1999-12-09
SK27299A3 (en) 2000-10-09
ZA977903B (en) 1999-03-03
HRP970478A2 (en) 1998-08-31
KR100338610B1 (ko) 2002-05-27
NZ334213A (en) 2000-08-25
NO991048D0 (no) 1999-03-03
EP0931075A1 (en) 1999-07-28
JP3554337B2 (ja) 2004-08-18
GT199700102A (es) 1999-02-25
WO1998009961A1 (en) 1998-03-12
BR9712005A (pt) 1999-08-24
HUP9903248A3 (en) 2000-07-28
JP2000502724A (ja) 2000-03-07
TNSN97148A1 (fr) 2005-03-15
MA26439A1 (fr) 2004-12-20
TR199900481T2 (xx) 1999-06-21
HRP970478B1 (en) 2002-10-31
DZ2303A1 (fr) 2002-12-28
ID18157A (id) 1998-03-05
BG64447B1 (en) 2005-02-28
BG103195A (en) 1999-09-30
CN1234031A (zh) 1999-11-03
AP795A (en) 1999-12-28
PE107998A1 (es) 1999-01-30
EA002113B1 (ru) 2001-12-24
CO4600636A1 (es) 1998-05-08
HUP9903248A2 (hu) 2000-04-28
AP9701080A0 (en) 1997-10-31
HN1997000126A (es) 1997-12-26

Similar Documents

Publication Publication Date Title
NO991048L (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
MY132499A (en) Substituted indazole derivatives and related compounds
CA2258285A1 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
ZA200206191B (en) Pyrimidine compounds.
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
NO20020391L (no) 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater
HRP20070020T3 (en) 1-(2h-pyrazol-3-yl)-3- 4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl -urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
CA2401812A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
ATE211740T1 (de) Substituierte indazolderivate
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
IL153748A0 (en) Processes for preparing azacycloalkanoylaminothiazole derivatives
WO2002059109A3 (en) Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases
NO924806L (no) Etanoladdukter av 6-sulfonylsubstituerte 3-hydroksykromaner og deres anvendelse som inhalasjonsmiddel ved sykdommer
NO20035026D0 (no) Dihydroimidazo [5,1-A]-<beta>-karbolinderivater, fremgangsmåte til deres fremstilling og anvendelse derav som legemiddel
CZ155096A3 (en) Aminoalkylaminopyridine derivatives, process of their preparation and pharmaceutical composition containing thereof
ECSP972158A (es) Analogos de indazol sustituido